TY - JOUR T1 - Response to: ‘Is chondroitin sulfate plus glucosamine superior to placebo in the treatment of knee osteoarthritis?’ by Zeng <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e57 LP - e57 DO - 10.1136/annrheumdis-2015-207482 VL - 74 IS - 9 AU - Marc C Hochberg Y1 - 2015/09/01 UR - http://ard.bmj.com/content/74/9/e57.abstract N2 - We would like to thank Zeng et al1 for their comments on the Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES)2 and the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT)3 and its long-term follow-up.4In MOVES,2 glucosamine plus chondroitin sulfate was non-inferior to celecoxib (primary outcome: mean decrease in Western Ontario and McMaster (WOMAC) pain score) in 606 patients with knee osteoarthritis with moderate–severe pain. A placebo arm was not included because celecoxib, the reference treatment, had proven efficacy versus placebo in knee osteoarthritis, for example5 ,6; so, this was felt to be unethical and unnecessary. While Zeng et al1 agreed with this decision, they brought up some interesting points.The original 24-week … ER -